阳光诺和(688621.SH)：ABA001注射液临床试验申请获得受理

智通财经01-21

智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司及全资子公司北京阿尔纳科技有限公司收到国家药品监督管理局核准签发的《受理通知书》，在研项目ABA001注射液的临床试验申请获得受理。ABA001注射液拟申报适应症为高血压。ABA001 注射液为靶向血管紧张素原(AGT)的信使RNA(mRNA)基因的小干扰核苷酸药物，偶联N-乙酰半乳糖胺(N-Acetylgalactosamine...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2605717202?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-21 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605717202","market":"us","top_or_hot":-1,"title":"阳光诺和(688621.SH)：ABA001注射液临床试验申请获得受理","media":"智通财经","content":"<div>\n<p>智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司及全资子公司北京阿尔纳科技有限公司收到国家药品监督管理局核准签发的《受理通知书》，在研项目ABA001注射液的临床试验申请获得受理。ABA001注射液拟申报适应症为高血压。ABA001 注射液为靶向血管紧张素原(AGT)的信使RNA(mRNA)基因的小干扰核苷酸药物，偶联N-乙酰半乳糖胺(N-Acetylgalactosamine...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1395638.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阳光诺和(688621.SH)：ABA001注射液临床试验申请获得受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阳光诺和(688621.SH)：ABA001注射液临床试验申请获得受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-21 17:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1395638.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司及全资子公司北京阿尔纳科技有限公司收到国家药品监督管理局核准签发的《受理通知书》，在研项目ABA001注射液的临床试验申请获得受理。ABA001注射液拟申报适应症为高血压。ABA001 注射液为靶向血管紧张素原(AGT)的信使RNA(mRNA)基因的小干扰核苷酸药物，偶联N-乙酰半乳糖胺(N-Acetylgalactosamine...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1395638.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688621","symbol_name":"阳光诺和","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1395638.html","article_id":"2605717202","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605717202","pubTimestamp":1768986489,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，阳光诺和 发布公告，近日，公司及全资子公司北京阿尔纳科技有限公司收到国家药品监督管理局核准签发的《受理通知书》，在研项目ABA001注射液的临床试验申请获得受理。ABA001注射液拟申报适应症为高血压。同类siRNA药物Zilebesiran的临床研究已证实该机制的有效性与安全性，单次给药疗效可持续24周，为ABA001注射液的开发提供了充分的科学依据。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688621":"阳光诺和","BK0216":"研究试验"},"translate_title":"Sunshine Novo (688621. SH): ABA001 injection clinical trial application accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688621":1.5},"content_text":"智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司及全资子公司北京阿尔纳科技有限公司收到国家药品监督管理局核准签发的《受理通知书》，在研项目ABA001注射液的临床试验申请获得受理。ABA001注射液拟申报适应症为高血压。ABA001 注射液为靶向血管紧张素原(AGT)的信使RNA(mRNA)基因的小干扰核苷酸药物，偶联N-乙酰半乳糖胺(N-Acetylgalactosamine，GalNAc)递送系统，可精准地将药物递送至肝脏细胞，通过siRNA的干扰沉默机制，从源头靶向沉默AGT的信使RNA，阻断AGT蛋白的合成，从根本上抑制肾素-血管紧张素-醛固酮系统(Renin-Angiotensin-Aldosterone System，RAAS)升高血压的作用，从而降低血压。同类siRNA药物Zilebesiran的临床研究已证实该机制的有效性与安全性，单次给药疗效可持续24周，为ABA001注射液的开发提供了充分的科学依据。非临床研究表明，本品1mg/kg即可显著降低血压，动物耐受良好，具有较高的安全性，有望实现每3个月或半年给药一次的长效降压效果，其长效给药特性有望突破现有治疗瓶颈，为高血压患者提供更优治疗选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605717202","isCrawlerRequest":true}